QSC RESEARCH GRADE
≥99% HPLC PurityMS ConfirmedJanoshik COA5-Region Domestic ShippingSelective Tumour Lysis
What is PNC-27 10mg?
PNC-27 is a 32-amino acid chimeric anticancer peptide containing a p53 HDM-2-binding domain fused to a membrane-destabilising penetratin sequence. It binds HDM-2 (human MDM-2) expressed on the plasma membrane of cancer cells — an expression pattern absent in normal cells — inducing selective membranolysis of tumour cells via a pore-forming mechanism. This selectivity makes PNC-27 a highly specific research tool for studying cancer cell membrane disruption and MDM-2-targeted therapy without affecting normal cell viability.
Research Applications
Selective Tumour Cell Lysis Research
PNC-27 lyses cancer cell lines expressing plasma membrane HDM-2 while sparing normal cells. Standard in vitro readouts: LDH release assay, PI exclusion, MTT viability across cancer vs normal cell panels.
MDM-2/p53 Pathway Research
PNC-27 exploits cancer-specific plasma membrane HDM-2 expression — distinct from nuclear MDM-2 p53 degradation. Research into membranous MDM-2 as a cancer-specific target.
Cancer Cell Line Selectivity Profiling
Mapping HDM-2 plasma membrane expression across cancer cell lines to identify PNC-27-responsive tumour types — pancreatic, breast, and melanoma lines show high sensitivity.
Quick Specs
| Product | PNC-27 10mg × 10 Vials (100mg total) |
| Mechanism | HDM-2 binding + membranolysis |
| Format | Lyophilised powder, 10-vial kit |
| Purity | ≥99% HPLC, MS confirmed |
| Storage | −20°C lyophilised; 4°C reconstituted |
